Indazole-3-carboxamide and -3-carboxylic acid derivatives.

A compound of formula (I), or a pharmaceutically acceptable salt thereof:

![Chemical Structure]

wherein
- X is CO and Y is NH or O;
- R₂ is hydrogen, C₃₋₇ alkyl, C₆₋₇ alkenyl-methyl, phenyl or phenyl C₁₋₄ alkyl either of which phenyl moieties may be substituted by one or two of halogen, CF₃, C₁₋₆ alkoxy or C₁₋₆ alkyl;
- R₁ is hydrogen, halogen, CF₃, C₁₋₆ alkyl or C₁₋₆ alkoxy;
- R₃ is a group of formula (a), (b) or (c):
wherein $n$ is 2 or 3;
p and $q$ are independently 1 to 3;
and
$R_4$ or $R_5$ is $C_{1-3}$ alkyl.
This invention relates to novel compounds having pharmacological activity, to processes for their preparation and their use as pharmaceuticals.

This is a divisional application of European Patent Application No. 86302964.1 in the name of Beecham Group p.l.c. (EP publn No. 200444), the subject matter of which is wholly incorporated herein by reference.

The invention is described with reference to EP-A-200444 and the claims which follow.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:

$$\begin{align*}
X Y - R_2 \\
\text{(I)}
\end{align*}$$

wherein
X is CO and Y is NH or O;
R_3 is hydrogen, C_1-6 alkyl, C_3-7 alkenyl-methyl, phenyl or phenyl C_1-4 alkyl either of which phenyl moieties may be substituted by one or two of halogen, CF_3, C_1-6 alkoxy or C_1-6 alkyl;
R_1 is hydrogen, halogen, CF_3, C_1-6 alkyl or C_1-6 alkoxy;
R_2 is a group of formula (a), (b) or (c):

(a)

(b)

(c)

wherein n is 2 or 3;
p and q are independently 1 to 3;
and
R_4 or R_5 is C_1-3 alkyl.

2. A compound according to claim 1 wherein R_2 is a group of formula (a).

3. A compound according to claim 2 wherein Y-R_2 is in the endo-configuration.

4. A compound according to claim 1 wherein R_2 is a group of formula (c) wherein q is 1 or 2.
5. A compound according to any one of claims 1 to 4 wherein R₃ is hydrogen or methyl.

6. A compound according to any one of claims 1 to 5 wherein R₁ is hydrogen or 5-halo.

7. 3-Indazolecarboxylic acid (endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ester,
   N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)indazole-3-carboxamide,
   1-methyl-3-indazolecarboxylic acid(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ester,
   N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-5-fluorindazole-3-carboxamide,
   N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-5-chlorindazole-3-carboxamide,
   5α-N-(2-methyl-2-azabicyclo[2.2.2]oct-5-yl)-1-methylindazole-3-carboxamide,
   N-(exo-2-methyl-2-azabicyclo[2.2.1]hept-5-yl)-1-methylindazole-3-carboxamide,
   N-(endo-2-methyl-2-azabicyclo[2.2.1]hept-5-yl)-1-methylindazole-3-carboxamide, or
   a pharmaceutically acceptable salt of any of the foregoing.

8. A compound of formula (1) wherein R₂ is of formula (a) or (c) as defined in claim 1, but wherein R₄ or R₅ is replaced by hydrogen.

9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. Use of a compound according to any one of claims 1 to 7 in the manufacture of a medicament for use as a 5-HT antagonist.
### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (Int. CL4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO-A-8 501 048 (SANDOZ AG)</td>
<td>1,9,10</td>
<td>C07D451/12</td>
</tr>
<tr>
<td></td>
<td>* claims *</td>
<td></td>
<td>C07D451/14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C07D453/06</td>
</tr>
<tr>
<td>A</td>
<td>WO-A-8 400 166 (SANDOZ AG)</td>
<td>1,9,10</td>
<td>C07D401/12</td>
</tr>
<tr>
<td></td>
<td>* claims *</td>
<td></td>
<td>C07D401/04</td>
</tr>
<tr>
<td>E</td>
<td>EP-A-0 214 772 (BEECHAM GROUP PLC)</td>
<td>1,9,10</td>
<td>A61K31/46</td>
</tr>
<tr>
<td></td>
<td>* example 4 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>EP-A-0 223 385 (BEECHAM GROUP PLC)</td>
<td>1,9,10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* complete document *</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims.

Place of search: THE HAGUE

Date of completion of the search: 22 MAY 1992

Examiner: VAN BIJLEN H.